Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targe...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-08, Vol.7 (35), p.57327-57350
Main Authors: Fratta, Elisabetta, Montico, Barbara, Rizzo, Aurora, Colizzi, Francesca, Sigalotti, Luca, Dolcetti, Riccardo
Format: Article
Language:English
Subjects:
Acetylation
Antineoplastic Agents - therapeutic use
Azacitidine - analogs & derivatives
Azacitidine - pharmacology
DNA Methylation
Epigenesis, Genetic
Female
Hematologic Neoplasms - genetics
Histones - chemistry
Humans
Lymphoma, T-Cell, Cutaneous - genetics
Lymphoma, T-Cell, Cutaneous - therapy
Male
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - therapy
Protein Domains
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that "epigenetic drugs" are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination therapies are ongoing. The aim of this review is to provide a comprehensive summary of known epigenetic alterations and of the current use of epigenetic drugs for the treatment of hematological malignancies.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.10033